Histological features and severity of oxaliplatin-induced liver injury and clinical associations

Journal of Digestive Diseases

Volumn 15, Issue 10, 2014, Pages 553-560

  Nalbantoglu, Ilke ^a   Tan, Benjamin R ^a   Linehan, David C ^a   Gao, Feng ^b   Brunt, Elizabeth M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

Author keywords

Liver sinusoid; Oxaliplatin; Scoring

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CD34 ANTIGEN; IRINOTECAN; KI 67 ANTIGEN; LIVER ENZYME; OXALIPLATIN; WARFARIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; CANCER SURGERY; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; EVALUATION STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HEMATOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER FAILURE; LIVER FUNCTION TEST; LIVER INJURY; LIVER RESECTION; MALE; METASTATIC COLORECTAL CANCER; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PLEURA EFFUSION; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN EXPRESSION; SMALL INTESTINE OBSTRUCTION; STEATOSIS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; COLORECTAL TUMOR; DRUG-INDUCED LIVER INJURY; LIVER NEOPLASMS; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; SEVERITY OF ILLNESS INDEX;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATECTOMY; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MALE; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84911473753     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12177     Document Type: Article

References (25)

1. Adam R, Aloia T, Lévi F etal. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25: 4593-4602.
2. Narita M, Oussoultzoglou E, Chenard MP etal. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol 2012; 19: 2230-2237.
3. Nordlinger B, Sorbye H, Glimelius B etal. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016.
4. Wolf PS, Park JO, Bao F etal. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J Am Coll Surg 2013; 216: 41-49.
5. Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist 2009; 14: 1095-1105.
6. Aloia T, Sebagh M, Plasse M etal. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990.
7. Nakano H, Oussoultzoglou E, Rosso E etal. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247: 118-124.
8. Ribero D, Wang H, Donadon M etal. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110: 2761-2767.
9. Brouquet A, Benoist S, Julie C etal. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009; 145: 362-371.
10. Rubbia-Brandt L, Audard V, Sartoretti P etal. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466.
11. Klonowski PW, Tan B, Linehan DC, Porembka MR, Brunt EM. Capillarization of hepatic sinusoids after neoadjuvant therapy. Lab Invest 2010; 90: 360A.
12. Rubbia-Brandt L. Sinusoidal obstruction syndrome. Clin Liver Dis 2010; 14: 651-668.
13. Rubbia-Brandt L. Hepatic lesions induced by systemic chemotherapy for digestive cancer. Ann Pathol 2010; 30: 421-425 (in French).
14. Rubbia-Brandt L, Lauwers GY, Wang H etal. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56: 430-439.
15. Kleiner DE, Brunt EM, Van Natta M etal.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
16. Arotçarena R, Calès V, Berthelémy P etal. Severe sinusoidal lesions: a serious and overlooked complication of oxaliplatin-containing chemotherapy? Gastroenterol Clin Biol 2006; 30: 1313-1316.
17. Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 2008; 34: 1231-1236.
18. Yeong ML, Wakefield SJ, Ford HC. Hepatocyte membrane injury and bleb formation following low dose comfrey toxicity in rats. Int J Exp Pathol 1993; 74: 211-217.
19. Vreuls CP, Van Den Broek MA, Winstanley A etal. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology 2012; 61: 314-318.
20. Slade JH, Alattar ML, Fogelman DR etal. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 2009; 8: 225-230.
21. Tamandl D, Klinger M, Eipeldauer S etal. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 2011; 18: 421-430.
22. Ryan P, Nanji S, Pollett A etal. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol 2010; 34: 784-791.
23. Robinson SM, Mann J, Vasilaki A etal. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol 2013; 59: 318-326.
24. Rubbia-Brandt L, Tauzin S, Brezault C etal. Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther 2011; 10: 687-696.
25. Pilgrim CH, Brettingham-Moore K, Pham A etal. mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury. HPB (Oxford) 2011; 13: 811-816.